TechnoPhage announces FDA Fast Track Designation granted to TP-102 for the treatment of patients with infected diabetic foot ulcers.
Phico Therapeutics raises £7 million investment to support SASPject novel engineered phage technology
Phico Therapeutics raises £7 million investment to support SASPject advancement, novel engineered phage technology for next-generation antibiotics to curb antimicrobial resistance (AMR).
The National Institute of Allergy and Infectious Diseases (NIAID), has awarded 12 institutes with grants towards phage therapy research.
Phico Therapeutics receives funding from CARB-X towards the development of engineered bacteriophage with SASP gene targeting Pseudomonas aeruginosa.
Cytophage announced the beginning of animal testing of their throat and nasal phage spray that targets the COVID-19 virus.
TechnoPhage announced the beginning of Phase I/IIa study of TP-102 phage therapy to treat Diabetic Foot Infections (DPI).